Amicus Therapeutics Inc's Chief Development Officer Sells Shares
On December 20, 2023, Jeff Castelli, Chief Development Officer of Amicus Therapeutics Inc (NASDAQ:FOLD), sold 19,154 shares of the company, according to a recent SEC Filing. This transaction was part of the insider's trading activities over the past year, during which the insider sold a total of 19,154 shares and made no purchases.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. The company's lead product includes therapies for the treatment of Fabry and Pompe disease, as well as programs for other rare and orphan diseases.
The insider transaction history for Amicus Therapeutics Inc shows a pattern of insider selling, with 46 insider sells and no insider buys over the past year.
On the day of the insider's recent sale, shares of Amicus Therapeutics Inc were trading at $13.24, giving the company a market cap of $3.767 billion.
The stock's price-to-GF-Value ratio stands at 0.99, indicating that Amicus Therapeutics Inc is fairly valued based on its GF Value of $13.37.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is calculated considering historical trading multiples, a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
